In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI-Designated Cancer Centers

Page Options

  • Print This Page
  • Email This Document

Popular Resources

Roswell Park Cancer Institute

Donald L. Trump, M.D., FACP
President & CEO

Elm & Carlton Streets
Buffalo, New York 14263
Main: (716) 845-2300
Physician Referral: 1-800-767-9355 (1-800-ROSWELL)
General Information: 1-877-275-7724 (1-877-ASK-RPCI)

Visit Website

Roswell Park Cancer Institute
Buffalo, New York

Roswell Park Cancer Institute (RPCI) was the first cancer center in the United States when it was founded in 1898 by Dr. Roswell Park. In 1974, RPCI received its NCI designation as a comprehensive cancer center. RPCI also serves as a member of the National Comprehensive Cancer Network.

For many years, RPCI has asserted the importance of translational research, taking a multidisciplinary approach to cancer research with scientists and clinicians working closely together. The Institute’s goal of reducing the burden of cancer has led to the development of close cooperation among basic/translational research, multidisciplinary oncology teams, and educational programs.

Over the past decade, RPCI has undergone significant growth, adding 250 new clinical and laboratory faculty, a new research building, and a Clinical Research Center dedicated to Phase I cancer clinical trials. Over this time period, the Institute has experienced a 300% increase in clinical revenues, a 198% increase in grant revenues, and a 95% increase in outpatient visits. RPCI is one of the preeminent centers in this country to take a cancer drug from its early development stages through clinical trials.

RPCI’s research encompasses six major programs: Cancer Prevention and Population Sciences; Cell Stress and Biophysical Therapies; Genetics; Genitourinary Cancer; Tumor Immunology; and Immunotherapy. Program members are drawn from basic science, clinical, and population science departments.

Current areas of research include: developing vaccines against ovarian cancer; designing novel aromatase inhibitors; investigating the anti-cancer effects of vitamin D on lung, prostate, and bladder tumors; conducting Phase I clinical trials and seeking FDA-approval for new drugs against metastatic solid tumors; overseeing the Transdisciplinary Tobacco Use Research Center, an international research collaboration devoted to reducing the disease burden of tobacco use; and participating in the North Carolina-Louisiana Prostate Cancer Project, a multi-institutional collaboration designed to illuminate the causes of racial differences in prostate cancer outcomes.

In addition, RPCI has established several biotech spin-off companies and has formed strategic partnerships with investigators and centers throughout the world. The Institute is active in global health issues, including leading a national anti-tobacco campaign in Hungary, which has the highest rate of lung cancer in Europe. The Institute also has a formal agreement with institutions in Nigeria to improve cancer treatment—with an RPCI surgeon performing Nigeria’s first radical prostatectomy in 2011—and a collaboration with other international academic institutions, such as the University of Puerto Rico, to exchange faculty and students to improve education.

Because RPCI has developed a seamless interface between scientific inquiry and clinical applications—including an active clinical trials program—patients in Buffalo and western New York are afforded access to promising breakthroughs in cancer diagnostics, technologies, and therapies.

Most recently, RPCI released Quality 2011, its first comprehensive report card on its clinical trends and outcomes, as well as key quality indicators that contribute significantly to a positive experience for RPCI’s patients and their families.

* This profile was provided by the Roswell Park Cancer Institute.